Amgen Inc (AMG.SG)
| Previous close | 257.15 |
| Open | 293.00 |
| Bid | 287.40 x 200000 |
| Ask | 288.25 x 300000 |
| Day's range | 289.50 - 295.90 |
| 52-week range | 197.70 - 303.00 |
| Volume | |
| Avg. volume | 164 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Yahoo FinanceAmgen's peek at its GLP-1 drug trial results heightens competition in obesity market
Competition is heating up in the GLP-1 space as Amgen gets closer to the finish line with its candidate.
- Yahoo Finance Video
Weight-loss drug competition heats up. Is Wegovy in trouble?
The competition among weight-loss drugs is heating up as Amgen (AMGN) reports positive early results from the development of its GLP-1 weight-loss drug, MariTide. The pharmaceutical company also topped first-quarter revenue estimates despite reporting a loss of $113 million. Yahoo Finance Senior Health Reporter Anjalee Khemlani breaks down how competition in the obesity drug market is ramping up as drug manufacturers find new medical use cases for this class of drugs. She refers back to comments made by Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen — Novo Nordisk makes Wegovy and Ozempic — and Eli Lilly (LLY) CEO Dave Ricks — Eli Lilly makes Zepbound and Mounjaro — to Yahoo Finance over the past several months. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Melanie Riehl
Simply Wall St.Amgen First Quarter 2024 Earnings: EPS Misses Expectations
Amgen ( NASDAQ:AMGN ) First Quarter 2024 Results Key Financial Results Revenue: US$7.45b (up 22% from 1Q 2023). Net...
